Literature DB >> 13590423

Fluoxymesterone therapy in advanced breast cancer.

B J KENNEDY.   

Abstract

Entities:  

Keywords:  BREAST NEOPLASMS/therapy; FLUDROCORTISONE/related compounds

Mesh：

Substances：

Year:  1958        PMID： 13590423     DOI： 10.1056/NEJM195810022591404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

Review 1.  Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Authors:  Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina
Journal:  Endocr Relat Cancer       Date:  2015-02-26       Impact factor: 5.678

2.  Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells.

Authors:  Eleanor F Need; Luke A Selth; Tiffany J Harris; Stephen N Birrell; Wayne D Tilley; Grant Buchanan
Journal:  Mol Endocrinol       Date:  2012-09-28

3.  Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat.

Authors:  S Dauvois; S M Li; C Martel; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

4.  Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.

Authors:  R Poulin; D Baker; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

5.  Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide.

Authors:  G Boccuzzi; E Tamagno; E Brignardello; M Di Monaco; M Aragno; O Danni
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

Authors:  F Labrie; S Li; A Bélanger; J Côté; Y Mérand; M Lepage
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Androgen receptor as a targeted therapy for breast cancer.

Authors:  Joseph P Garay; Ben H Park
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

8.  Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells.

Authors:  M Di Monaco; E Brignardello; L Leonardi; V Gatto; G Boccuzzi
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.

Authors:  Theresa E Hickey; Luke A Selth; Kee Ming Chia; Geraldine Laven-Law; Heloisa H Milioli; Daniel Roden; Shalini Jindal; Mun Hui; Jessica Finlay-Schultz; Esmaeil Ebrahimie; Stephen N Birrell; Suzan Stelloo; Richard Iggo; Sarah Alexandrou; C Elizabeth Caldon; Tarek M Abdel-Fatah; Ian O Ellis; Wilbert Zwart; Carlo Palmieri; Carol A Sartorius; Alex Swarbrick; Elgene Lim; Jason S Carroll; Wayne D Tilley
Journal:  Nat Med       Date:  2021-01-18       Impact factor: 53.440

10.  The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Authors:  Joseph P Garay; Bedri Karakas; Abde M Abukhdeir; David P Cosgrove; John P Gustin; Michaela J Higgins; Hiroyuki Konishi; Yuko Konishi; Josh Lauring; Morassa Mohseni; Grace M Wang; Danijela Jelovac; Ashani Weeraratna; Cheryl A Sherman Baust; Patrice J Morin; Antoun Toubaji; Alan Meeker; Angelo M De Marzo; Gloria Lewis; Andrea Subhawong; Pedram Argani; Ben H Park
Journal:  Breast Cancer Res       Date:  2012-02-09       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.